{
    "organizations": [],
    "uuid": "23ed724cea7146094d19a64fae917c3912bdcf7b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-us-fda-expands-approval-of-imfinzi/brief-u-s-fda-expands-approval-of-imfinzi-to-reduce-the-risk-of-non-small-cell-lung-cancer-progressing-idUSFWN1Q61DS",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA Expands Approval Of Imfinzi To Reduce The Risk Of Non-Small Cell Lung Cancer Progressing",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 16 (Reuters) - AstraZeneca Plc:\n* U.S. FDA EXPANDS APPROVAL OF IMFINZI TO REDUCE THE RISK OF NON-SMALL CELL LUNG CANCER PROGRESSING\n* FDA - GRANTED THE APPROVAL OF IMFINZI TO ASTRAZENECA‍​ Source text: ( bit.ly/2EL2FKl ) Further company coverage:\n ",
    "published": "2018-02-17T05:56:00.000+02:00",
    "crawled": "2018-02-17T14:49:34.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "astrazeneca",
        "plc",
        "fda",
        "expands",
        "approval",
        "imfinzi",
        "reduce",
        "risk",
        "cell",
        "lung",
        "cancer",
        "progressing",
        "fda",
        "granted",
        "approval",
        "imfinzi",
        "source",
        "text",
        "company",
        "coverage"
    ]
}